229 related articles for article (PubMed ID: 35283387)
21. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
22. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Steven NM; Fisher BA
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
[TBL] [Abstract][Full Text] [Related]
23. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
24. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
[TBL] [Abstract][Full Text] [Related]
25. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
27. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis.
Xu Y; Song Y; Liu X; Shi Y; Liu Y; Qian H; Gao X; Chen M; Pan R; Zhao J; Zhong W; Wu W; Wang M
Cancer Commun (Lond); 2022 Sep; 42(9):902-905. PubMed ID: 35678260
[No Abstract] [Full Text] [Related]
28. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
29. Infectious complications in patients treated with immune checkpoint inhibitors.
Karam JD; Noel N; Voisin AL; Lanoy E; Michot JM; Lambotte O
Eur J Cancer; 2020 Dec; 141():137-142. PubMed ID: 33137589
[TBL] [Abstract][Full Text] [Related]
30. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
31. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
32. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology.
Attieh RM; Nunez B; Copeland-Halperin RS; Jhaveri KD
Cardiorenal Med; 2024; 14(1):281-293. PubMed ID: 38684145
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
34. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients.
Tajiri K; Sekine I
Jpn J Clin Oncol; 2022 Jul; 52(7):659-664. PubMed ID: 35348725
[TBL] [Abstract][Full Text] [Related]
35. Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.
Nagata S; Hamaji M; Ozasa H; Yamada Y; Ohsumi A; Date H
Clin Lung Cancer; 2022 Jul; 23(5):e321-e324. PubMed ID: 35649818
[No Abstract] [Full Text] [Related]
36. Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
Hadfield MJ; Mistry H; Pelcovits A; Bansal R; Andrea S; Chergui A; Ramphal K; Austin M; Khurshid H
Am J Clin Oncol; 2023 Apr; 46(4):183-184. PubMed ID: 36959209
[No Abstract] [Full Text] [Related]
37. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Immunotherapy; 2020 Nov; 12(16):1183-1193. PubMed ID: 32878511
[No Abstract] [Full Text] [Related]
38. Complications of immuno-oncology care: what urologist should know.
Grajales V; Martini A; Shore ND
BJU Int; 2024 May; 133(5):524-531. PubMed ID: 38437876
[TBL] [Abstract][Full Text] [Related]
39. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
40. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
